Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer

drugsDecember 12, 2019

Tag: HER2 , metastatic breast cancer , tucatinib

PharmaSources Customer Service